AIMS
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and chronic heart failure (CHF). Despite clinical guideline recommendations, SGLT2i uptake in UK primary care remains suboptimal and information on utilisat...
Chelsea Stefanska, R. Chung, Salman Ramjaun et al.· Diabetes, obesity and metabo...· 0 citations
Abstract Background Digital interventions offer scalable alternatives to traditional face-to-face diabetes education, but often face challenges related to inconsistent clinical effectiveness, and declining user engagement. However, whether a digital structured education program integrated with behavioral nudge tools ca...
Yan Lin, Ying-Chun Zeng, Kaining Chen et al.· JMIR mHealth and uHealth· 0 citations
The global prevalence of diabetes is rising rapidly, with the steepest increases and greatest unmet need occurring in low-income and middle-income countries. Despite strong evidence that early detection and continuous management reduce morbidity and mortality, many health systems face persistent gaps in diagnosis, trea...
Partha Kar, H. Sathanapally, P. Aschner et al.· The Lancet Diabetes and Endo...· 0 citations
Objective To examine and contrast the associations of glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) with the risk of cardiometabolic multiple long-term conditions (cMLTC) and evaluate their incremental predictive utility. Patients and Methods The study analyzed 2233 adults (mean age 63; 1009 (45.2%) men)...
S. Seidu, S. Kunutsor, K. Khunti· Mayo Clinic Proceedings: Inn...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
